A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients

Nucci, M.;Biasoli, I.;Akiti, T.;Silveira, F.;Solza, C.;Barreiros, G.;Spector, N.;Derossi, A.;Pulcheri, W.

Author address: 

Nucci, M, Hosp Univ Clementino Fraga Filho, Hematol Serv, Av Brigadeiro Trompovsky, BR-21941590 Rio De Janeiro, Brazil


To evaluate the efficacy of itraconazole capsules in prophylaxis for fungal infections in neutropenic patients, we conducted a prospective, double-blind, placebo-controlled, randomized trial. Patients with hematologic malignancies or those who received autologous bone marrow transplants were assigned either a regimen of itraconazole (100 mg orally twice daily; n = 104) or of placebo (n = 106). Overall, fungal infections (superficial or systemic) occurred more frequently in the placebo group (15% vs. 6%; P=.03), There were no differences in the empirical use of amphotericin B or systemic fungal infections. Among patients with neutropenia that was profound (

abstract No: 


Full conference title: 

38th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • ICAAC 38th